Human pharmacokinetic and pharmacodynamic profiles of leuprorelin acetate depot in prostatic cancer patients.

@article{Mazzei1990HumanPA,
  title={Human pharmacokinetic and pharmacodynamic profiles of leuprorelin acetate depot in prostatic cancer patients.},
  author={Teresita Mazzei and Enrico Mini and Marco Rizzo and Piero Periti},
  journal={The Journal of international medical research},
  year={1990},
  volume={18 Suppl 1},
  pages={42-56}
}
A total of 21 patients with advanced prostatic cancer and one patient with benign prostatic hypertrophy received 3.75, 7.5 or 15 mg leuprorelin acetate depot subcutaneously. Serum leuprorelin concentrations increased immediately after injection, reaching a peak concentration (range 13.1-54.5 ng/ml), which was directly proportional to dose, within 3 h. Mean drug levels subsequently declined to a plateau directly proportional to dose at 5 weeks. There was also a significant (P less than 0.01… CONTINUE READING